Abstract: The disclosure is directed to an isolated polynucleotide encoding a modified picornavirus 3C protease, wherein the modified picornavirus 3C protease includes an altered secondary structure and one or more amino acid substitution(s) located at one or more amino acid position(s) corresponding to positions 16-25, 99-100 and 115-130 of a wild-type Fool-and-Mouth Disease Virus (FMDV) 3C protease, wherein the isolated polynucleotide encoding the modified picornavirus 3C protease, when transformed into and co-expressed in a host cell, enhances transgene expression of a P1 precursor polypeptide in comparison to an amount of P1 precursor polypeptide transgene expression exhibited in a host cell transformed and co-expressed with a control picornavirus 3C protease, wherein the one or more corresponding amino acid position(s) is/are identified by an alignment of the modified picornavirus 3C protease with the one or more of the wild type FMDV 3C protease(s).
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
May 24, 2022
Assignee:
The Government of the United States of America as represented by the Secretary of Homeland Security
Abstract: The disclosure provides an active peptide with an anti-lipid oxidation function and a preparation method and application thereof and belongs to the technical field of plant-derived biologically active peptides. In the disclosure, oil processing by-products, namely oil crops after oil extraction, are used as the raw materials, and the raw materials are subjected to the steps of protein extraction, infrared pretreatment, proteolysis, freeze-drying, lipophilic part extraction, vacuum concentration and drying to prepare an anti-lipid oxidation peptide having the functional characteristics of scavenging DPPH free radicals, chelating metal ions, inhibiting lipid peroxidation, prolonging vegetable oil oxidation induction time, improving emulsion stability and the like.
Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.
Type:
Grant
Filed:
May 20, 2019
Date of Patent:
February 15, 2022
Assignees:
Ipsen Bioinnovation Limited, Allergan, Inc.
Inventors:
Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.
Abstract: Methods for enhancing phytase thermal stability by fusing binding elements to target phytases are provided. Engineered phytases that include binding elements fused to target phytases to cause cyclization of the engineered phytases and enhance thermal stability of the target phytases are described. Engineered nucleic acids encoding engineered phytases and hosts engineered to express engineered nucleic acids are also provided. Methods for incorporating engineered phytases in animal feed and animal feed including the same are described.
Type:
Grant
Filed:
May 6, 2020
Date of Patent:
February 8, 2022
Assignee:
AGRIVIDA, INC.
Inventors:
R. Michael Raab, Gabor Lazar, Binzhang Shen
Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 1, 2022
Assignee:
Polaris Group
Inventors:
Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
Abstract: A liquid or dried granulated milk clotting aspartic protease enzyme composition and process for isolating a milk clotting aspartic protease enzyme of interest.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
February 1, 2022
Assignee:
CHR. HANSEN A/S
Inventors:
Martin Lund, Jonas Jacobsen, Johannes Maarten Van Den Brink
Abstract: A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
Abstract: The disclosure relates, in general, to Glycogen Storage Disease Type VI and, in particular, to a method of treating Glycogen Storage Disease Type VI and to compounds and compositions suitable for use in such a method.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
January 4, 2022
Assignee:
Duke University
Inventors:
Yuan-Tsong Chen, Priya Kishnani, Baodong Sun
Abstract: Disclosed herein are modified strains for reducing degradation of recombinantly expressed products secreted from a host organism and methods of using the modified strains. In some embodiments, to attenuate a protease activity in Pichia pastoris, the genes encoding enzymes the degrade proteases are inactivated or mutated to reduce or eliminate activity. In preferred strains, the protease activity of proteases encoded by PAS_chr4_0584 (YPS1-1) and PAS_chr3_1157 (YPS1-2) (e.g., polypeptides comprising SEQ ID NO: 66 and 67) is attenuated.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
January 4, 2022
Assignee:
Bolt Threads, Inc.
Inventors:
Matthew Scott Gamboa, Joshua Tyler Kittleson
Abstract: Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).
Abstract: The present invention provides a tool which exhibits excellent properties in the quantification of autophagy activity. A unimolecular FRET probe of the present invention includes an acceptor consisting of a fluorescent protein to be enzymatically degraded inside a lysosome or a vacuole; and a donor having an amino acid sequence having a sequence identity of 95% or more with respect to an amino acid sequence represented by SEQ ID NO: 1.
Abstract: The present invention is directed generally to cell-targeted cytotoxic constructs comprising a targeting polypeptide, a linking polypeptide and a cytotoxic polypeptide. Preferably, (a) the targeting polypeptide is a R-spondin1 (RSPO1), R-spondin2 (RSPO2) or yoked chorionic gonadotropin (YCG), the linking polypeptide comprises LPXT (SEQ ID NO: 56) or NPXT (SEQ ID NO: 60) as well as others, where X is any amino acid, the linking polypeptide being positioned between the targeting ligand and (c) the cytotoxic moiety is an auristatin or a truncated serine protease, the serine protease having an IIGG (SEQ ID NO: 91), IVGG (SEQ ID NO: 92) or ILGG (SEQ ID NO: 93) at its N-terminus. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer).
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
December 7, 2021
Assignee:
Research Development Foundation
Inventors:
Xinjian Lin, Xiying Shang, Stephen B. Howell
Abstract: Reaction compositions are disclosed herein comprising at least water, alpha-glucose-1-phosphate (alpha-G1P), an acceptor molecule, and a beta-1,3-glucan phosphorylase enzyme. These reactions can synthesize oligosaccharides and polysaccharides with beta-1,3 glycosidic linkages. Further disclosed are methods of isolating beta-1,3-glucan.
Abstract: The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
Type:
Grant
Filed:
August 17, 2020
Date of Patent:
November 23, 2021
Assignee:
Codexis, Inc.
Inventors:
Goutami Banerjee, Jie Yang, Xiyun Zhang, Erika M. Milczek, Melissa Ann Mayo, Stephan Jenne
Abstract: A method for rapidly and highly sensitively measuring endotoxin relies on an endotoxin-measuring agent, which includes a factor C derived from Tachypleus tridentatus that does not have His-tag sequence at the C-terminus, a factor B of a horseshoe crab, and a proclotting enzyme of a horseshoe crab. Each of these proteins can be a recombinant protein obtainable by being expressed using a stably expressing cell line of an insect cell as a host.
Type:
Grant
Filed:
May 18, 2018
Date of Patent:
November 2, 2021
Assignee:
Seikagaku Corporation
Inventors:
Hikaru Mizumura, Maki Aizawa, Toshio Oda
Abstract: Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
October 5, 2021
Assignee:
Novo Nordisk Healthcare AG
Inventors:
Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
Abstract: In a dishwashing liquid, the cleaning performance, in particular on bleachable stains such as, for example, tea stains, is to be improved. This succeeds using a dishwashing liquid which comprises a hydrogen peroxide source, a bleaching catalyst and a protease that, in native electrophoresis on a polyacrylamide gel, has a migration distance that is longer than the migration distance of the protease as per SEQ ID NO. 1.
Type:
Grant
Filed:
January 4, 2017
Date of Patent:
August 31, 2021
Assignee:
HENKEL IP & HOLDING GMBH
Inventors:
Nina Mussmann, Thomas Eiting, Thorsten Bastigkeit, Konstantin Benda, Hendrik Hellmuth, Thomas Weber